Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance, discusses the importance of making sure oncology practices are educated about their value-based enterprise exception when mailing patients their cancer medications.
Mid-May is when oncology practices need to ensure they are not violating the Stark law by mailing oncology medications, says Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance.
Transcript
What topic did you talk about when you cohosted a webinar on Davis Enterprise and why is it important to COA?
With the public health emergency that will be ending in May, we were made aware that CMS has put out an FAQ alerting practices that, when they mail order their oncology medications, that would be in violation of the Stark law. And so, while they've been protected up to this point—and prior to that there was an in-office ancillary exception—this will not be covered under that. What we're looking at is the value-based enterprise exception, that when a practice is able to document that they meet certain criteria for value-based enterprise, that they will be permitted to still continue to mail order oncology prescriptions out to their cancer patients.
How many practices will be affected by this?
Oh, quite a few, any community practice. If they're mailing prescriptions and they’re pharmacy owned or they’re provider owned, then they could be in violation of Stark exception by mailing this out. So quite a few will definitely be impacted. Any medically integrated pharmacy will be impacted by this.
What is the time frame for all of this?
Mid-May is when—we call it a PHE, which is the public health emergency—when that's lifted on or about May 11, that's when we're going to start to have to worry about this. We're trying to get practices educated and set up prior to that date. And it is really important that they use a legal counsel to do this. So, while we'll provide that information for them, they will need to work with a lawyer to make sure that they're documenting and, like I said, hitting certain criteria for this value-based enterprise exception.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More